Abingworth raises US-$465m for new life sc...The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies. more ➔
Two companies aim for 2nd-gen COVID vaccin...As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines. more ➔
Rentschler Biopharma to produce 100m doses...German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV. more ➔
Italian Enthera Pharma raise €35m in Ser...Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the companys investor syndicate. more ➔
German antibodies in demand in USAA US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2. more ➔
Omnix Medical bags €10.8m from EIC Accer...Israels Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs. more ➔
Germany orders antibody therapies from USAGermany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly. more ➔
Servier and MiNA Therapeutics sign €220m...French Servier SA and the UKs MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders. more ➔
LSP leads €21m round into Neurent Medica...Irish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners. more ➔
Janssen presents one-shot COVID-19 vaccine...J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine. more ➔